Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control
- 1 December 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (18), 2489-2491
- https://doi.org/10.1097/00002030-200212060-00020
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV LipoatrophyA Randomized TrialJAMA, 2002
- Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated LipodystrophyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infectionAIDS, 2000
- The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophyAIDS, 1999
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Epidemiological and clinical aspects of the metabolic complications of HIV infection The fat redistribution syndromeAIDS, 1999
- Abnormal fat distribution and use of protease inhibitorsThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998